The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Clinical research
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials
EuroIntervention 2013;9:709-720 published online ahead of print April 2013. DOI: 10.4244/EIJV9I6A115
Bill D. Gogas1,2, MD; Christos V. Bourantas1, MD, PhD; Hector M. Garcia-Garcia3, MD, MSc, PhD; Yoshinobu Onuma1, MD; Takashi Muramatsu1, MD, PhD; Vasim Farooq1, MBChB; Roberto Diletti1, MD; Robert-Jan M. van Geuns1, MD, PhD; Bernard De Bruyne4, MD, PhD; Bernard Chevalier5, MD; Leif Thuesen6, MD; Pieter C. Smits7, MD, PhD; Dariusz Dudek8, MD; Jacques Koolen9, MD, PhD; Stefan Windecker10, MD; Robert Whitbourn11, MD; Dougal McClean12, MD; Cecile Dorange13, MS
B.D. Gogas and C.V. Bourantas contributed equally to this manuscript.
Aims: To assess serially the edge vascular response (EVR) of a bioresorbable vascular scaffold (BVS) compared to a metallic everolimus-e